UCSF Benioff Children's Hospital Antimicrobial Susceptibility Gram-negatives Inpatient/ED

PrintPrintPDFPDF

N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, MER-meropenem, P/T-piperacillin-tazobactam

Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.

Susceptibilities are based on combined data from 2015-2017. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate. 

Organism Total Isolates

CZOL

%S

(95% CI)

CTRX

%S

(95% CI)

CTAZ

%S

(95% CI)

CFPM

%S

(95% CI)

GEN

%S

(95% CI)

TOB

%S

(95% CI)

T/S

%S

(95% CI)

CIP

%S

(95% CI)

P/T

%S

(95% CI)

MER

%S

(95% CI)

Acinetobacter baumanii

6*  N/A

17

(0,64)

 100

(54,100)

 83

(36,100)

100

(54,100)

100

(54,100)

 100

(54,100)

 100

(54,100)

67

(22,96)

100

(54,100)

Citrobacter freundii

15*

N/A

60

(32,84)

73

(45,92)

93

(68,100)

87

(60,98)

87

(60,98)

80

(52,96)

93

(68,100)

93

(68,100)

100

(78,100)

Enterobacter aerogenes

24*

N/A

N/A

N/A

100

(86,100)

100

(86,100)

100

(86,100)

100

(86,100)

100

(86,100)

80

(56,94)

100

(83,100)

Enterobacter cloacae

77

N/A

N/A

N/A

97

(91,100)

100

(95,100)

100

(95,100)

94

(86,98)

100

(95,100)

86

(76,93)

100

(95,100)

Escherichia coli

487

66**

(62,71)

90

(86,92)

92

(89,94)

96

(93,97)

91

(89,94)

93

(90,95)

69

(64,73)

90

(86,92)

98

(97,99)

100

(99,100)

Klebsiella oxytoca

41

22**

(11,38)

100

(91,100)

100

(91,100)

100

(91,100)

100

(91,100)

100

(91,100)

93

(80,98)

100

(91,100)

100

(91,100)

100

(91,100)

Klebsiella pneumoniae

108

75**

(66,83)

92

(85,96)

94

(88,98)

97

(92,99)

94

(88,98)

97

(92,99)

79

(70,86)

95

(90,98)

96

(91,99)

100

(97,100)

Proteus mirabilis

50

12**

(5,24)

100

(93,100)

100

(93,100)

100

(93,100)

94

(84,99)

94

(84,99)

90

(79,97)

100

(93,100)

100

(93,100)

100

(93,100)

Pseudomonas aeruginosa

118***

N/A

N/A

86

(79,92)

91

(84,95)

N/A

99

(95,100)

N/A

94

(88,98)

85

(77,91)

87

(80,93)

ICU

49

N/A

N/A

82

(68,91)

88

(75,95)

N/A

98

(89,100)

N/A

90

(78,97)

80

(66,90)

86

(73,94)

non-ICU

69

N/A

N/A

90

(80,96)

93

(84,98)

N/A

100

(95,100)

N/A

97

(90,100)

88

(78,95)

88

(78,95)

Serratia marcescens

33

N/A

100

(89,100)

100

(89,100)

100

(89,100)

97

(84,100)

97

(84,100)

97

(84,100)

100

(89,100)

94

(80,99)

100

(89,100)

*When fewer than 30 isolates are reported, % susceptible may not reflect robust estimate of population susceptibility

**Reporting of Cefazolin susceptibility for E. coli, Klebsiella spp and Proteus is based on breakpoints for complicated infections - see outpatient E. coli susceptibilities for reporting based on uncomplicated UTI breakpoints

***Pseudomonas aeruginosa isolates do not include isolates from patients with cystic fibrosis.